PRECISION: Celecoxib Similar to Ibuprofen, Naproxen for CV Risk PRECISION: Celecoxib Similar to Ibuprofen, Naproxen for CV Risk
Celecoxib hit its noninferiority CV mark against ibuprofen and naproxen in arthritis patients at increased CVD risk, but not all are convinced.Heartwire from Medscape
Conclusion: Very limited evidence to support recreational activity and walking intervention was found for knee osteoarthritis, in the short-term on pain and physical function, respectively.
This article is protected by copyright. All rights reserved
ARTHRITIS symptoms include joint swelling and inflammation. This £1 fruit could help to reduce some of the condition’s painful effects.
A new study of 50,000 people finds that those with rheumatoid arthritis had a 47 percent higher risk of COPD hospitalization than the general population.
Condition: Rheumatoid Arthritis Interventions: Other: Patient Educational Intervention; Other: Patient Control Sponsors: University of Alabama at Birmingham; Pfizer Independent Grants for Learning and Change Enrolling by invitation
Recent studies suggest that canabidiol oil (CBD oil) could play a role in treating arthritis. What are the benefits CBD oil and are there any side effects?
(RAND Corporation) Biosimilar drugs have been touted as one strategy to help curb the runaway costs of biologics that have advanced the treatment of illness such as rheumatoid arthritis and many cancers. A new study finds biosimilars could cut health care spending in the United States by $54 billion over the next decade. The savings are about 20 percent larger than a similar, widely cited analysis done three years ago by the same researchers.
This article gives a brief review about the etiopathogenesis and clinical presentation of the common inflammatory dermatoses associated with HIV such as psoriasis, reactive arthritis, seborrheic dermatitis, eosinophilic folliculitis, pruritic papular eruption, photosensitivity disorders prurigo nodularis, atopic dermatitis, and ichthyosis.
Chronic inflammatory arthropathies, such as rheumatoid arthritis (RA), spondyloarthritis, including psoriatic arthritis (PsA), ankylosing spondyloarthritis (AS), osteoarthritis (OA), and intervertebral disc degenerative disease (DDD) constitute major public health problems that are anticipated to grow significantly as the human population ages. However, many aspects concerning the molecular mechanisms underlying their onset and progression remain unclear.
Introducing“biosimilar” versions of complex biologic drugs used to treat illnesses such as cancer and rheumatoid arthritis could cut health care spending in the United States by $54 billion over the next decade.